Andrew J. Dunbar

Oncology
210 Ashville Ave # 408
Cary, NC 27518

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications

Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy.

Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy.

Journal: Cancer
Published: January 28, 2026

Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase.

Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase.

Journal: Blood advances
Published: April 18, 2025

Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML.

Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML.

Journal: Blood
Published: July 31, 2024

NCCN Guidelines® Insights: Systemic Mastocytosis, Version 3.2024.

NCCN Guidelines® Insights: Systemic Mastocytosis, Version 3.2024.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: June 11, 2024

Developing a membrane-proximal CD33-targeting CAR T cell.

Developing a membrane-proximal CD33-targeting CAR T cell.

Journal: Journal for immunotherapy of cancer
Published: April 11, 2024

Suppression of IL-1β promotes beneficial accumulation of fibroblast-like cells in atherosclerotic plaques in clonal hematopoiesis.

Suppression of IL-1β promotes beneficial accumulation of fibroblast-like cells in atherosclerotic plaques in clonal hematopoiesis.

Journal: Nature cardiovascular research
Published: February 16, 2024

A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.

A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.

Journal: Blood advances
Published: April 26, 2023

Non-canonical Hedgehog signaling mediates profibrotic hematopoiesis-stroma crosstalk in myeloproliferative neoplasms.

Non-canonical Hedgehog signaling mediates profibrotic hematopoiesis-stroma crosstalk in myeloproliferative neoplasms.

Journal: Cell reports
Published: March 01, 2023

In vivo models of subclonal oncogenesis and dependency in hematopoietic malignancy.

In vivo models of subclonal oncogenesis and dependency in hematopoietic malignancy.

Journal: Cancer cell
Published: February 14, 2023

Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia.

Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia.

Journal: Blood advances
Published: January 12, 2023

Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.

Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: September 08, 2022

Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms.

Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms.

Journal: Cancer discovery
Published: August 26, 2022
Showing 1-12 of 30

Last Updated: 09/26/2026